摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1aS,12R,13aS,18aR,Z)-12-((8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl)oxy)-1a,4,5,6,7,8,11,12,13,13a-decahydro-14H,16H,18H-cyclopropa[e]oxazolo[3,4-d]pyrrolo[1,2-a][1,4]diazacyclotetradecine-9,14,16,18(1H)-tetraone | 1079097-92-9

中文名称
——
中文别名
——
英文名称
(1aS,12R,13aS,18aR,Z)-12-((8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl)oxy)-1a,4,5,6,7,8,11,12,13,13a-decahydro-14H,16H,18H-cyclopropa[e]oxazolo[3,4-d]pyrrolo[1,2-a][1,4]diazacyclotetradecine-9,14,16,18(1H)-tetraone
英文别名
——
(1aS,12R,13aS,18aR,Z)-12-((8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl)oxy)-1a,4,5,6,7,8,11,12,13,13a-decahydro-14H,16H,18H-cyclopropa[e]oxazolo[3,4-d]pyrrolo[1,2-a][1,4]diazacyclotetradecine-9,14,16,18(1H)-tetraone 化学式
CAS
1079097-92-9
化学式
C34H35ClN4O7S
mdl
——
分子量
679.193
InChiKey
JWXFJULKIOSWKC-KUWGUDSOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.28
  • 重原子数:
    47.0
  • 可旋转键数:
    5.0
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    128.23
  • 氢给体数:
    0.0
  • 氢受体数:
    10.0

反应信息

  • 作为反应物:
    描述:
    1-甲基环丙烷磺酰胺(1aS,12R,13aS,18aR,Z)-12-((8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl)oxy)-1a,4,5,6,7,8,11,12,13,13a-decahydro-14H,16H,18H-cyclopropa[e]oxazolo[3,4-d]pyrrolo[1,2-a][1,4]diazacyclotetradecine-9,14,16,18(1H)-tetraone 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下, 以 四氢呋喃 为溶剂, 生成 N-{17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yloxy]-2,14-dioxo-3,15-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carbonyl}-(1-methylcyclopropyl)sulfonamide
    参考文献:
    名称:
    Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors
    摘要:
    Starting from the previously reported HCV NS3/4A protease inhibitor BILN 2061 (1), we have used a fast-follower approach to identify a novel series of HCV NS3/4A protease inhibitors in which (i) the P3 amino moiety and its capping group have been truncated, (ii) a sulfonamide is introduced in the P1 cyclopropyl amino acid, (iii) the position 8 of the quinoline is substituted with a methyl or halo group, and (iv) the ring size of the macrocycle has been reduced to 14 atoms. SAR analysis performed with a limited set of compounds led to the identification of N-{17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin4-yloxy]-2,14-dioxo-3,15-diazatricyclo [13.3.0.0 [Bartenschlager, R.; Lohmann, V. J. Gen. Virol. 2000, 81, 1631; Vincent Soriano, Antonio Madejon, Eugenia Vispo, Pablo Labarga, Javier Garcia-Samaniego, Luz Martin-Carbonero, Julie Sheldon, Marcelle Bottecchia, Paula Tuma, Pablo Barreiro Expert Opin. Emerg. Drugs, 2008, 13, 1-19]]octadec-7-ene-4-carbonyl}(1-methylcyclopropyl)(1-methylcyclopropyl) sulfonamide 19l an extremely potent (K-i = 0.20 nM, EC50 = 3.7 nM), selective, and orally bioavailable dipeptide NS3/4A protease inhibitor, which has features attractive for further preclinical development. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.07.124
  • 作为产物:
    参考文献:
    名称:
    Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors
    摘要:
    Starting from the previously reported HCV NS3/4A protease inhibitor BILN 2061 (1), we have used a fast-follower approach to identify a novel series of HCV NS3/4A protease inhibitors in which (i) the P3 amino moiety and its capping group have been truncated, (ii) a sulfonamide is introduced in the P1 cyclopropyl amino acid, (iii) the position 8 of the quinoline is substituted with a methyl or halo group, and (iv) the ring size of the macrocycle has been reduced to 14 atoms. SAR analysis performed with a limited set of compounds led to the identification of N-{17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin4-yloxy]-2,14-dioxo-3,15-diazatricyclo [13.3.0.0 [Bartenschlager, R.; Lohmann, V. J. Gen. Virol. 2000, 81, 1631; Vincent Soriano, Antonio Madejon, Eugenia Vispo, Pablo Labarga, Javier Garcia-Samaniego, Luz Martin-Carbonero, Julie Sheldon, Marcelle Bottecchia, Paula Tuma, Pablo Barreiro Expert Opin. Emerg. Drugs, 2008, 13, 1-19]]octadec-7-ene-4-carbonyl}(1-methylcyclopropyl)(1-methylcyclopropyl) sulfonamide 19l an extremely potent (K-i = 0.20 nM, EC50 = 3.7 nM), selective, and orally bioavailable dipeptide NS3/4A protease inhibitor, which has features attractive for further preclinical development. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.07.124
点击查看最新优质反应信息

同类化合物

马杜霉素II 雷帕霉素 长川霉素 达福普丁甲磺酸 西罗莫司脂化物 西罗莫司异构体C 蛎灰菌素A 柠檬提取物 子囊霉素 威里霉素 唑他莫司 吡美莫司 双氢他克莫司 去甲氧基雷帕霉素 去甲基他克莫司 化合物 T32504 化合物 T25424 依维莫司EP杂质E 依维莫司 他克莫司杂质5 他克莫司开环杂质 他克莫司31-DMT 他克莫司 乌米里莫斯 FK-506一水合物 8-表他克莫司 8,9,14,15,24,25,26,26alpha-八氢-14-羟基-4,12-二甲基-3-(1-甲基乙基)-(3R,4R,5E,10E,12E,14S,26alphaR)-3H-21,18-次氮基-1H,22H-吡咯并[2,1-c][1,8,4,19]二氧杂二氮杂二十四环-1,7,16,22(4H,17H)-四酮 7-去甲氧基-7-乙氧基-42-O-(2-羟基乙基)雷帕霉素 42-O-[2-[[羟基[2-(三甲基铵)乙氧基]亚膦酰基]氧基]乙基]雷帕霉素内盐 42-(二甲基亚膦酰)雷帕霉素 42-(2-四唑基)雷帕霉素 40-O-[2-(叔丁基二甲硅基)氧代]乙基雷帕霉素 37-去亚甲基24,33-二-O-(叔-丁基二甲基硅烷基)-37-氧代-FK-506 31-O-去甲基-Fk506 28-O-甲基-雷帕霉素 24,33-二-O-(叔-丁基二甲基硅烷基)-37,38-去氢-37,38-二羟基-FK-506 24,32-双-O-(tert-butyldimethylsilyl)-他克莫司 22-羟基-33-叔-丁基二甲基硅烷基氧基-异-FK-506 2-甲氧基-5-硝基嘧啶-4-胺 2-异丙基-2-甲基噁丙环 2,6-二(1-甲基丙基)-p-甲苯酚 19-表FK-506 15-O-去甲基长川霉素 13-O-去甲基子囊霉素 13,15-O-二去甲基长川霉素 (E/Z)-FK-50626,28-烯丙酸酯 (9Z)-8-乙基-5,15,19-三羟基-3-[(E)-2-(4-羟基-3-甲氧基环己基)-1-甲基乙烯基]-14-甲氧基-4,10,12,18-四甲基-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-十六氢-3H-16,19-环氧吡啶并[2,1-c][1,4]噁吖环二十三英-1,7,20,21(4H,23H)-t (4R,7R,8R,9Z,14E,16E,18S)-18-羟基-7-异丙基-4,8,16-三甲基-6,23-二氧杂-3,12,25-三氮杂双环[20.2.1]二十五-1(24),9,14,16,22(25)-五烯-2,5,11,20-四酮 (2S,5S,6R,10R,11S)-10-庚基-6-羟基-4,11-二甲基-5-(苯基甲基)-2-丙-2-基-1,9-二氧杂-4-氮杂环十二烷-3,8,12-三酮 (1R,2R,4S)-4-{(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-二羟基-19,30-二甲氧基-15,17,21,23,29,35-六甲基-2,3,10,14,20-五氧代-11,36-二氧杂-4-氮杂三环[30.3.1.04,9]三十六碳-16,24,26,28-四烯-12-基]丙基}-2-甲氧基环己基2,2,5-三甲基-1,3-二恶烷-5-羧酸酯